↓ Skip to main content

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over

Overview of attention for article published in Vaccine, June 2004
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy
1 policy source
twitter
12 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
52 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over
Published in
Vaccine, June 2004
DOI 10.1016/j.vaccine.2003.11.052
Pubmed ID
Authors

Heath Kelly, John Attia, Ross Andrews, Richard F. Heller

Abstract

The number needed to treat (NNT) and population extensions of the NNT describe the population outcomes of disease treatment, usually for chronic diseases. We have developed similar measures for vaccine preventable diseases based on the number needed to vaccinate. These measures quantify the number of people, or the number of vaccine doses, needed to prevent one event due to disease per year and allow the calculation of the vaccine cost to prevent one event due to disease per year. We used this method to compare influenza and pneumococcal vaccine programmes for people aged 65 years or more. We calculated the vaccine cost (dollars AUD) to prevent a case of disease, a hospitalisation or a death due to influenza or invasive pneumococcal disease each year in this age group. For influenza, the vaccine costs were dollars 598 to prevent one case per year, dollars 10787 per hospitalisation prevented and dollars 74801 per death prevented each year. We assumed all cases of invasive pneumococcal disease were hospitalised so the vaccine cost of dollars 11494 per case prevented was the same as the vaccine cost per hospitalisation prevented, while the vaccine cost per death prevented each year was dollars 49972. These results suggest the vaccine costs for the prevention of one hospitalisation or one death each year due to invasive pneumococcal disease among the elderly in Australia would be similar to the costs for the prevention of one hospitalisation or death due to influenza.

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Denmark 1 2%
Unknown 50 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 21%
Student > Master 8 15%
Student > Ph. D. Student 6 12%
Professor > Associate Professor 5 10%
Student > Bachelor 5 10%
Other 12 23%
Unknown 5 10%
Readers by discipline Count As %
Medicine and Dentistry 26 50%
Agricultural and Biological Sciences 7 13%
Mathematics 2 4%
Social Sciences 2 4%
Computer Science 1 2%
Other 4 8%
Unknown 10 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2021.
All research outputs
#1,909,397
of 18,964,669 outputs
Outputs from Vaccine
#1,563
of 14,011 outputs
Outputs of similar age
#32,030
of 304,869 outputs
Outputs of similar age from Vaccine
#30
of 179 outputs
Altmetric has tracked 18,964,669 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,011 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,869 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.